Horizon Therapeutics PLC (OQ:HZNP)

May 21, 2020 09:15 am ET
Horizon Therapeutics Named Number One Best Workplace in Chicago
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named No. 1 on the Great Place to Work® “Best Workplaces in Chicago 2020” list in the small and medium category. The list includes 39 other top small-to-medium sized companies, as well as 40 be
May 21, 2020 08:00 am ET
Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that multiple case series and studies will be presented at the Annual European Congress of Rheumatology (EULAR 2020), being held virtually June 3 - 6, 2020. Several presentations of clinical trial data and in-practice cases will provide results on KRYSTEXXA® (pegloticase injection) with commonly used immunomodulators to help more people with chronic gout refractory to conventional therapies – also known as uncontrolled gout – potentially achieve complete and durable response to treatment.
May 19, 2020 08:00 am ET
Horizon Therapeutics to Participate in Upcoming Investor Conferences
Horizon Therapeutics (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences:
May 14, 2020 09:00 am ET
New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that provide important insights into the mechanisms of TEPEZZA™ (teprotumumab-trbw), illustrating its pharmacokinetic (PK) profile and supporting the dosing regimen established in the labeling for the treatment of Thyroid Eye Disease (TED). A separate abstract summarizes the first U.S.-based validation of the Graves' Ophthalmopathy Quality of Life (GO-QOL) questionnaire. Both studies were accepted as poster presentations at ENDO 2020, the Endocrine Society’s annual meeting. They were also published in a special supplement of the
May 11, 2020 12:00 pm ET
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a U.S. physician survey showing that endocrinologists and ophthalmologists perceive Thyroid Eye Disease (TED) to have a significant burden on their patients’ quality of life (QOL). TED is a serious, progressive and vision-threatening rare autoimmune disease associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation and facial disfigurement.1 The analysis was accepted as a poster presentation at the AACE 29th Annual Scientific & Clinical Congress and was published
May 06, 2020 09:31 am ET
Thinking about trading stocks or options in Beyond Meat, Horizon Therapeutics, Overstock.com, Peloton, or Immunomedics?
NEW YORK, May 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, HZNP, OSTK, PTON, and IMMU....
May 06, 2020 07:00 am ET
Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Ye
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its first-quarter 2020 financial results. The Company increased its full-year 2020 net sales guidance and revised its adjusted EBITDA guidance.
Apr 27, 2020 08:10 am ET
Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets are now available in the United States and can be ordered in 75 mg and 300 mg dosage strengths for adults and children one year of age and older living with nephropathic cystinosis. The U.S. Food and Drug Administration (FDA) approved this new dosage form in February 2020.
Apr 15, 2020 08:00 am ET
Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2020 financial results will be released on Wednesday, May 6, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Apr 09, 2020 09:00 am ET
Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®.
Apr 02, 2020 08:00 am ET
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Under terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. CZN001 was originally discovered and developed by Sanofi, which is eligible to receive contingent payments upon the
Mar 31, 2020 12:00 pm ET
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the recently approved medicine effectively reduces proptosis (eye bulging) in patients with Thyroid Eye Disease (TED) regardless of age, gender and smoking status. The analysis was accepted for presentation during an oral session at ENDO 2020, the Endocrine Society’s annual meeting, and will also be published in a special supplemental section of the Journal of the Endocrine Society. TEPEZZA – the first and only medicine appr
Mar 26, 2020 04:15 pm ET
Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.
Mar 03, 2020 08:00 am ET
Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).
Feb 28, 2020 10:00 am ET
Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
Horizon Therapeutics (Nasdaq: HZNP) and Willis Towers Watson (Nasdaq: WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness of the crucial need to identify new medicines for the 30 million people living with rare diseases in the United States. The antennas will be illuminated in the colors of the rising sun (Horizon’s corporate colors) elevating Horizon’s commitment to partnering with the community to raise awareness and bring forward new medicines for rare diseases.
Feb 28, 2020 08:00 am ET
Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
Horizon Therapeutics plc (Nasdaq: HZNP) today announced a $1 million commitment over five years to establish the #RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases. The #RAREis scholarship will support the pursuit of life enrichment activities for adults living with rare diseases for a variety of educational pursuits, including educational courses, travel stipends for rare disease conferences and obtaining two-and four-year degrees.
Feb 26, 2020 07:00 am ET
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance.
Feb 18, 2020 08:30 am ET
Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
Feb 18, 2020 08:00 am ET
Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules.
Feb 11, 2020 08:00 am ET
Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting Athletes today announced a new partnership for the 2020 Reps for Rare Disease campaign, which offers an opportunity for NFL Draft prospects to give back and support the rare disease community. Participants who team up with Uplifting Athletes will dedicate their performance in one event – bench press, vertical jump or broad jump – at the NFL Scouting Combine or their school’s official pro day, to raising funds for rare disease research and awareness initiatives.
Feb 04, 2020 08:00 am ET
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Jan 28, 2020 11:10 am ET
Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the first quarter with additional terms of the purchase not disclosed. Horizon is expected to occupy the campus in the second half of this year.
Jan 24, 2020 04:05 pm ET
Horizon Therapeutics plc Announces Changes in Research and Development Organization
Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer.
Jan 22, 2020 05:20 pm ET
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the largest clinical program in TED and dem
Jan 21, 2020 03:04 pm ET
FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation and facial disfigurement. TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor
Jan 13, 2020 08:15 am ET
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates.
Jan 13, 2020 08:05 am ET
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Dec 13, 2019 04:01 pm ET
FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).
Dec 13, 2019 07:00 am ET
Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Company’s common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 a.m. to 4 p.m. ET to discuss teprotumumab, an investigational medicine for the treatment of Thyroid Eye Disease (TED). Teprotumumab is an investigational medicine and its safety and efficacy have not been established.
Dec 09, 2019 08:00 am ET
Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will present at 5 p.m. PT on Jan. 15, 2020.
Nov 22, 2019 08:00 am ET
Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
Horizon Therapeutics plc (Nasdaq: HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions.
Nov 21, 2019 08:00 am ET
Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to “Listen to Your Eyes”
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of “Listen to Your Eyes,” a new website and Facebook commun
Nov 14, 2019 09:30 am ET
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List
Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been named to FORTUNE Magazine’s 2019 “Best Workplaces for Parents” list, which highlights companies that best support employees, regardless of parenting status, as well as off
Nov 13, 2019 04:15 pm ET
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences:
Nov 11, 2019 08:00 am ET
Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a patient case series at the American College of Rheumatology (ACR) Annual Meeting illustrating that the addition of methotrexate to a course of therapy with KRYSTEXXA® (pegloticase injection) may help more people with chronic gout refractory to conventional therapies – also known as uncontrolled gout – achieve response to treatment. In addition, Horizon will present data describing the inflammatory impact of uric acid on other organs, including the liver and kidney.
Nov 08, 2019 09:30 am ET
The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
Horizon Therapeutics plc (Nasdaq: HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fif
Nov 06, 2019 07:00 am ET
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its third-quarter 2019 financial results and raised the midpoint of its full-year 2019 adjusted EBITDA guidance.
Nov 05, 2019 08:00 am ET
Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
Horizon Therapeutics plc (Nasdaq: HZNP) will join the leading voices in the nephrology community this week to inform and build data-based discourse on managing the challenges of gout and kidney disease during the American Society of Nephrology (ASN) Kidney Week, to be held Nov. 5-10 in Washington, D.C.
Nov 04, 2019 08:30 am ET
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Horizon Therapeutics plc (Nasdaq: HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). If approved, teprotumumab would be the first FDA-approved medicine for active TED. The Prescription Drug User Fee Act (PDUFA)
Nov 04, 2019 08:00 am ET
New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
Horizon Therapeutics plc (Nasdaq: HZNP) today announced multiple presentations that will highlight the serious, systemic effect of urate deposition and will inform strategies to optimize treatment of uncontrolled gout through immunomodulation during the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta.
Oct 31, 2019 10:00 am ET
Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
Horizon Therapeutics plc (Nasdaq: HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision), as well as improvements in quality of life (QoL). These data were presented at the 89th Annual Meeting of the American Thyroid Association (ATA). This is the first presentation of the pooled analyses and builds on the individual pos
Oct 24, 2019 11:15 am ET
Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain’s Chicago Business, ranking number two. C
Oct 24, 2019 08:00 am ET
New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc (Nasdaq: HZNP), will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.
Oct 17, 2019 09:00 am ET
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE Magazine’s 2019 “Best Medium Workplaces” list for the fourth consecutive year. Horizon ranked eighth out of 100 other medium sized companies.
Oct 17, 2019 08:00 am ET
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has initiated an open-label clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) in adults with chronic gout refractory to conventional therapies – also known as uncontrolled gout – who have undergone a kidney transplant to demonstrate that KRYSTEXXA may provide effective disease control without burdening the kidneys.
Oct 11, 2019 12:30 pm ET
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium, and build upon data
Oct 10, 2019 09:00 am ET
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
Today, in support of World Sight Day, Horizon Therapeutics plc (Nasdaq: HZNP) and Prevent Blindness launched a campaign that brings together the voices of the thyroid eye disease (TED) community to educate the public on how TED can damage vision and encourage people who are living with TED to put their vision first by sharing their experiences, monitoring the
Oct 09, 2019 08:00 am ET
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Oct 08, 2019 08:00 am ET
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium in San Francisco on Oct. 11.
Oct 03, 2019 08:00 am ET
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and number 2 in the pharmaceutical category. The list recognizes organizations with the most robust adoption benefit programs, comparing financial reimbursement and paid leave offered to employees who adopt, based on a survey of organizations across the United States. The full list can be found
Sep 09, 2019 08:00 am ET
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation. The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated with an accelerated six-month review period compared to the standard ten-month review p
Aug 28, 2019 04:30 pm ET
Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
DUBLIN – August 28, 2019 – Horizon Therapeutics plc (Nasdaq: HZNP) today named Andy Pasternak executive vice president, chief business officer, reporting directly to Timothy Walbert, chairman, president and chief executive officer, effective Nov. 1. Pasternak will join the Company’s executive committee and will lead business development, mergers and acquisitions, corporate strategy, commercial development and portfolio management.
Aug 19, 2019 09:00 am ET
American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)
A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for Horizon’s investigational medicine tepr
Aug 19, 2019 08:00 am ET
Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September:
Aug 14, 2019 08:00 am ET
Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.com, a go-to resource for the more than 350 million people around the world living with rare disease. This website is the latest expansion of Horizon’s #RAREis™ program, which aims to elevate the voices, faces and experiences of the rare disease community. The progra
Aug 07, 2019 07:00 am ET
Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its second-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.
Aug 01, 2019 10:45 am ET
Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the availability of an expanded access program for its investigational medicine teprotumumab. Developed in partnership with the U.S. Food and Drug Administration (FDA), the expanded access program may provide access to teprotumumab for people living with active thyroid eye disease (TED) who meet protocol criteria. The expanded access program will be available for a limited time while the FDA reviews Horizon’s Biologics License Application (BLA) for teprotumumab. Teprotumumab is an investigational medicine and its safety and efficacy have
Aug 01, 2019 08:00 am ET
Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has appointed Dr. Sue Mahony to its board of directors.
Jul 25, 2019 08:00 am ET
Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the company has won a Gold International CSR Excellence Award in the Large Business category for its partnership with Chicago-based school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be found here.
Jul 18, 2019 09:00 am ET
Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets. If approved by the FDA, this new dosage form would provide another option for patients, in addition to the currently available PROCYSBI delayed-release capsules. The capsules are FDA-approved for children one year of age and older and adults living with nephropathic cystinosis. The FDA is expected to make a decision on the approval of the proposed new dosage form
Jul 16, 2019 08:00 am ET
Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Jul 11, 2019 04:45 pm ET
Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes
Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. The note offering is expected to close on July 16, 2019, subject to the satisfaction of customary closing conditions.
Jul 10, 2019 07:30 am ET
Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027.
Jul 10, 2019 07:00 am ET
Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Horizon requested priority review for the application, which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing.
Jun 27, 2019 09:54 am ET
Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease
Today marks the launch of a new patient empowerment and disease education initiative called Eyes on Graves’, created to bring attention, education and resources to people living with Graves’ disease and/or thyroid eye disease (TED). In time for Graves’ Disease Awareness Month in July, Eyes on Graves’ was created through a new collaboration called the Graves’ and TED Council – a group of people living with both diseases and their loved ones whose mission is to raise awareness and understanding of Graves’ disease and TED among physicians, patients and caregivers, leading to improve
Jun 20, 2019 08:00 am ET
Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Jun 12, 2019 08:00 am ET
Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019
Horizon Therapeutics plc (Nasdaq: HZNP) is elevating the dialogue on gout within the medical and scientific community during the Annual European Congress of Rheumatology (EULAR 2019) with a series of data presentations on gout and its systemic implications. Oral and poster presentations reinforce the increasingly robust evidence linking gout to renal and cardiovascular health risks and raise important clinical considerations in monitoring and tracking patient status beyond joint health over time.
Jun 04, 2019 08:00 am ET
Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference
Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in June:
May 29, 2019 08:00 am ET
Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people who may have a UCD, including their family members. Horizon’s support of the UCD Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.
May 21, 2019 01:30 pm ET
Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “Best Workplaces in Chicago” list. Horizon ranked as one of the top 55 companies in the Chicago area.
May 16, 2019 08:00 am ET
Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease.
May 09, 2019 08:00 am ET
Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary. Tina will be honored today at the 30th annual Woman of the Year event in New York.
May 08, 2019 07:04 am ET
Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its first-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.
May 06, 2019 08:00 am ET
Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees.
Apr 26, 2019 02:00 pm ET
New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented as part of a late-breaking oral presentation at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress in Los Angeles. In addition to primary endpoint data previously
Apr 16, 2019 08:00 am ET
Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases
Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption Fund to help facilitate global adoptions of children with rare diseases. Children awaiting adoption with rare diseases often go untreated or receive minimal treatment, and many face life in a long-term care facility or nursing home, according to Gift of Adoption. The #RAREis Adoption Fund supports Gift of Adoption’s mission to provide financial assistance to complete the final steps of adoption of at-risk chil
Apr 12, 2019 08:00 am ET
Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress
Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress. The late-breaking oral presentation will be presented on Friday, April 26, 2019.
Apr 11, 2019 04:45 pm ET
Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work®
Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to Work® and FORTUNE Magazine. The company has also been awarded a
Apr 09, 2019 04:05 pm ET
Horizon Pharma plc to Release First-Quarter 2019 Financial Results and Host Webcast on May 8, 2019
Horizon Pharma plc (Nasdaq: HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Apr 04, 2019 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees.
Mar 18, 2019 08:00 am ET
Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be found here.
Mar 11, 2019 04:30 pm ET
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Horizon Pharma plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 14,081,632 of its ordinary shares at a price to the public of $24.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,836,734 additional ordinary shares. The estimated net proceeds to the Company from this offering are approximately $326.8 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company.
Mar 06, 2019 10:00 pm ET
Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares
Horizon Pharma plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 12,244,898 of its ordinary shares at a price to the public of $24.50 per share. The net proceeds to the Company from this offering are expected to be approximately $284 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,836,734 ordinary shares solely to cover over-allotments. The offering is ex
Mar 05, 2019 08:10 am ET
Analysis: Positioning to Benefit within The Goodyear Tire & Rubber, Cars, Tutor Perini, CVS Health, VMware, and Horizon Pharma Public — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of The Goodyear Tire & Rubber Company (NASDAQ:GT), Cars.com Inc. (NYSE:CARS),...
Mar 04, 2019 04:10 pm ET
Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares
Horizon Pharma plc (Nasdaq: HZNP) today announced that it is offering to sell $300,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of ordinary shares in the public offering solely to cover over-allotments.
Mar 01, 2019 05:50 pm ET
Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on March 1, 2018 of inducement restricted stock units for an aggregate of 8,544 ordinary shares to six new employees.
Feb 28, 2019 07:00 am ET
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints
Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent of teprotumumab patients compared to 9.5 percent of placebo patients achieved the primary endpoint of a 2 mm or more reduction in proptosis (p
Feb 27, 2019 07:00 am ET
Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance
Horizon Pharma plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2018 financial results and provided its full-year 2019 net sales and adjusted EBITDA guidance.
Feb 25, 2019 08:00 am ET
Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference
Horizon Pharma plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in March:
Feb 04, 2019 07:30 am ET
Report: Developing Opportunities within Southern, Horizon Pharma Public, Celestica, RCI Hospitality, Bluerock Residential Growth REIT, and Tilly's — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southern Company (NYSE:SO), Horizon Pharma Public Limited Company...
Jan 29, 2019 08:00 am ET
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019
Horizon Pharma plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2018 financial results will be released on Wednesday, Feb. 27, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Jan 03, 2019 08:00 am ET
Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout.
Dec 27, 2018 08:00 am ET
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with a urea cycle disorder (UCD).
Dec 17, 2018 08:00 am ET
Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the 37th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief executive officer, will present at 4:30 p.m. PT on Jan. 8, 2019.
Nov 29, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Mammoth Energy Services, Horizon Pharma Public, SBA Communications, International Flavors & Fragrances, WillScot, and Teekay Tankers — Discovering Underl
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mammoth Energy Services, Inc. (NASDAQ:TUSK), Horizon Pharma Public Limited...
Nov 16, 2018 08:00 am ET
Horizon Pharma plc to Participate in Upcoming Conferences
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences:
Nov 07, 2018 07:00 am ET
Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
Horizon Pharma plc (NASDAQ: HZNP) today announced its third-quarter 2018 financial results, confirmed its full-year 2018 net sales guidance range and increased its adjusted EBITDA guidance range.
Nov 02, 2018 09:30 am ET
The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace
Horizon Pharma plc (Nasdaq: HZNP) has been awarded a 2018 Top Workplaces honor by the Chicago Tribune.
Oct 29, 2018 05:57 pm ET
Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
Horizon Pharma plc (NASDAQ:HZNP) announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the American Academy of Ophthalmology (AAO) Annual Meeting, Oct. 27 – 30, 2018, in Chicago, Ill. The data was presented in an oral session, Diplopia Response in a Controlled Trial with Teprotumumab, an IGF-1 Receptor Antagonist Antibody for Thyroid Eye Disease, at 4:57 p.m. CT today.
Oct 25, 2018 01:00 pm ET
Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout. In addition, a retrospective analysis indicates that gout prevalence remains high among solid organ transplant patients, independent of the use of cyclosporine as an immunosuppressant. These data will be presented at the American Society of
Oct 25, 2018 08:00 am ET
Horizon Pharma plc to Participate in Investor Conferences in November
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences in November:
Oct 22, 2018 08:00 am ET
Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
Horizon Pharma plc (Nasdaq: HZNP) today announced that multiple studies demonstrating the extensive burden of uncontrolled gout and its impact on patients will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, Oct. 19-24, in Chicago. In addition to the data presentations, Horizon will host an academic lecture facilitated by prominent researchers on scientific advancements in the understanding of gout today at 1:30 p.m. CT at an ACR innovation theater.
Oct 19, 2018 08:50 am ET
Market Trends Toward New Normal in Endeavour Silver, Triton International, Resonant, Radware, Horizon Pharma Public, and Ensco plc — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Endeavour Silver Corporation (NYSE:EXK), Triton International Limited...
Oct 18, 2018 09:16 am ET
FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
Horizon Pharma plc (Nasdaq: HZNP) today announced that it has been named one of the 2018 Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the third consecutive year.
Oct 10, 2018 08:00 am ET
Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018
Horizon Pharma plc (Nasdaq: HZNP) announced today that its third-quarter financial results will be released on Wednesday, Nov. 7, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Oct 04, 2018 09:02 am ET
Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24 maintained these reductions 48 weeks following the study completion, or nearly a year off therapy. The results of this investigational medicine were presented during an oral session at the American Thyroid Association (ATA) Annual Meeting, Oct. 3 – 7, 2018, in Washington, D.C.
Sep 27, 2018 11:00 am ET
The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry
A prospective longitudinal natural history registry designed to provide long-term data evaluating people living with cystinosis was launched today at a meeting of The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) in Chicago, Ill. The registry will collect and organize physician-reported data that will help healthcare professionals better understand the natural history of cystinosis. Data collected will also be available to researchers exploring new potential treatments for cystinosis. Utilizing the established NAPRTCS
Sep 27, 2018 08:00 am ET
Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Horizon Pharma plc (Nasdaq: HZNP) enrolled the first patient in a clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) with methotrexate to sustain lower serum uric acid (sUA) levels of people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout – and increase persistence of efficacy on therapy. The clinical trial, Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR), will enroll approx
Sep 25, 2018 08:00 am ET
Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association
Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of moderate-to-severe active thyroid eye disease (TED). The data will be presented on Oct. 4, 2018, at the 2018 Annual Meeting of the American Thyroid Association (ATA) in Washington, D.C.
Sep 04, 2018 08:00 am ET
Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conference:
Sep 04, 2018 07:00 am ET
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and
Aug 21, 2018 08:10 am ET
Investor Expectations to Drive Momentum within Materialise NV, Southern First Bancshares, Ensco plc, Corbus Pharmaceuticals, TCP Capital, and Horizon Pharma Public — Discovering Underlying Factors of
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Materialise NV (NASDAQ:MTLS), Southern First Bancshares, Inc....
Aug 08, 2018 07:00 am ET
Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focu
Horizon Pharma plc (NASDAQ: HZNP) announced its second-quarter 2018 financial results today. Effective with the second quarter of 2018, the Company has realigned its operating structure and is reporting financial results as two separate segments: the orphan and rheumatology segment, its strategic growth business, and the primary care segment. The new operating structure reflects the evolution of the Company’s strategy and vision of transitioning Horizon Pharma to a biopharmaceutical company focused on rare disease medicines.
Jul 25, 2018 09:00 am ET
PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List
Horizon Pharma plc (Nasdaq: HZNP) today announced that the company has been named to PEOPLE’s “50 Companies That Care” list for 2018. The list will be featured in the August 6, 2018 print issue of PEOPLE Magazine, on newsstands nationwide on Friday, July 27. “50 Companies
Jul 16, 2018 08:30 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Horizon Pharma plc (Nasdaq: HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/944,398 and 15/944,416, both titled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs” that cover Horizon's U.S. approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid.
Jul 09, 2018 08:30 am ET
Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018
Horizon Pharma plc (Nasdaq: HZNP) announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Jun 15, 2018 05:45 am ET
Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
Horizon Pharma plc (NASDAQ:HZNP) presents multiple analyses of KRYSTEXXA® (pegloticase injection) clinical trial data underscoring the complex nature of chronic gout refractory to conventional therapies, also known as uncontrolled gout.  The data...
Jun 14, 2018 04:50 am ET
Epidemiologic Study Findings Show 27 Percent Increase in Emergency Department Visits for Gout in the United States Over the Past Decade
Results from a new study presented in an oral presentation at the Annual European Congress of Rheumatology (EULAR 2018) show a dramatic 27 percent increase in emergency department (ED) visits between 2006 and 2014 for people living with gout in the...
Jun 07, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind Horizon Pharma Public, Lululemon Athletica, Nordic American Tankers, UBS Group AG, 21Vianet Group, and Sandstorm Gold — New Horizons, Emerging Trends, and
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon Pharma Public Limited Company (NASDAQ:HZNP), Lululemon Athletica,...
Jun 04, 2018 08:00 am ET
Horizon Pharma plc and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention
Horizon Pharma plc (NASDAQ:HZNP) and the National Organization for Rare Disorders (NORD) today launched a new campaign recognizing rare disease innovation since the passing of the Orphan Drug Act in 1983.  Beginning today in the main lobby of the...
May 31, 2018 09:31 am ET
Thinking about buying stock in Apple, American Eagle Outfitters, Horizon Pharma, Micron or Verastem?
CHICAGO, May 31, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AEO, HZNP, MU, and VSTM....
May 30, 2018 08:00 am ET
Horizon Pharma plc to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 and will present at 10:40 a.m. PT. The presentation will be webcast live...
May 22, 2018 10:15 am ET
Horizon Pharma plc Named One of the Best Small and Medium Workplaces in Chicago by FORTUNE
Horizon Pharma plc (NASDAQ:HZNP) today announced that it has been selected to FORTUNE and Great Place to Work’s 2018 “Best Workplaces in Chicago” list. Horizon ranked number four out of 25 other small and medium sized companies. “It’s a great...
May 22, 2018 09:00 am ET
Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed, which was created to spotlight real-life stories of people living with uncontrolled gout, a painful and debilitating inflammatory form of arthritis...
May 09, 2018 07:00 am ET
Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare
Horizon Pharma plc (NASDAQ:HZNP) announced its first-quarter 2018 financial results today and increased its full-year 2018 net sales and adjusted EBITDA guidance.  The Company also announced that, effective in the second-quarter 2018, the Company...
May 08, 2018 08:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Horizon Pharma plc (Nasdaq:HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643 and 15/687,132, both entitled "Methods of Therapeutic...
May 04, 2018 08:00 am ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees....
May 03, 2018 08:00 am ET
Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star
Horizon Pharma plc (Nasdaq:HZNP) today announced that Sangita Iyer, director, financial planning and analysis, has been named a 2018 Healthcare Businesswomen's Association (HBA) Rising Star.  Sangita will be honored today at the 29th annual Woman...
May 01, 2018 08:00 am ET
Horizon Pharma plc to Participate in the UBS Global Healthcare Conference
DUBLIN, IRELAND, May 01, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the following conference in May:
Apr 12, 2018 04:30 pm ET
Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
-  Company also awarded “Best Places to Work in Chicago” and “10 Best Places to Work for Women” by Crain’s Chicago Business  -
Apr 11, 2018 08:20 am ET
New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and S
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd....
Apr 09, 2018 08:00 am ET
Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
DUBLIN, Ireland, April 09, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018.  Following the announcement, Horizon's management will host a live webcast at...
Apr 04, 2018 08:00 am ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, April 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Apr. 1, 2018 of inducement restricted stock units for an aggregate...
Mar 13, 2018 07:30 am ET
Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changyou, and China Yuchai International — Discovering Underlying Factors of In
NEW YORK, NY, March 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Methanex Corporation (NASDAQ:MEOH), YPF Sociedad...
Mar 06, 2018 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, March 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Mar. 1, 2018 of inducement restricted stock units for an aggregate...
Feb 28, 2018 07:00 am ET
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
-- Fourth-Quarter 2017 Net Sales of $274.2 Million;Fourth-Quarter 2017 Net Loss of $46.4 Million; Adjusted EBITDA of $102.7 Million --
Feb 27, 2018 06:00 pm ET
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns
DUBLIN, Ireland, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) to expand the approved indication for...
Feb 26, 2018 08:00 am ET
Horizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease Institute
The endowment will support a clinical care team dedicated to providing rare disease patients with earlier intervention and more consistent treatment over the course of their lifetimes
Feb 26, 2018 07:00 am ET
Horizon Pharma plc to Participate in the Cowen and Company 38th Annual Health Care Conference
DUBLIN, Ireland, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the company will present at the following conference in March:
Feb 22, 2018 09:00 am ET
Horizon Pharma plc Announces Release of the First RAREis™ Song in Partnership with Sing Me a Story Foundation and Global Genes
-- Yearlong partnership will create 20 songs from the stories of children living with rare diseases –
Feb 06, 2018 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Feb. 2, 2018 of inducement restricted stock units for an aggregate...
Jan 30, 2018 08:30 am ET
Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the launch of Cystinosis United, an initiative created for people living with nephropathic cystinosis, a rare genetic metabolic disease that causes the amino acid...
Jan 29, 2018 08:00 am ET
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
DUBLIN, Ireland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its fourth-quarter and full-year 2017 financial results will be released on Wednesday, Feb. 28, 2018.  Following the announcement, Horizon's management will host a...
Jan 08, 2018 07:05 am ET
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
-- Increases KRYSTEXXA®(pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ---- Increases Teprotumumab Estimated Peak Annual Net Sales to more than $750 Million ---- Confirms Expectation of more than 50 Percent Year-Over-Year Net Sales Growth for...
Jan 08, 2018 07:00 am ET
Jan 05, 2018 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on January 4, 2018 of inducement restricted stock units of 71,567 ordinary...
Jan 04, 2018 07:30 am ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Jan. 1, 2018 of inducement restricted stock units for an aggregate...
Dec 27, 2017 08:00 am ET
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic
DUBLIN, Ireland, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for PROCYSBI® (cysteamine bitartrate) delayed-release capsules to include children one...
Dec 18, 2017 09:23 am ET
Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that...
Dec 05, 2017 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that...
Nov 30, 2017 04:05 pm ET
Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that...
Nov 30, 2017 06:00 am ET
Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated medicines that address unmet medical needs, today named Shao-Lee Lin, M.D.,...
Nov 10, 2017 09:30 am ET
Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
DUBLIN, Ireland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it...
Nov 07, 2017 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that...
Nov 07, 2017 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Nov. 6, 2017 of inducement restricted stock units for an aggregate of 57,565 ordinary shares to 20 new employees....
Nov 06, 2017 12:00 pm ET
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions --
Nov 06, 2017 07:00 am ET
Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
-- Third-Quarter 2017 Net Sales of $271.6 Million --
Nov 04, 2017 11:00 am ET
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced results...
Nov 03, 2017 11:00 am ET
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today presented a...
Nov 02, 2017 04:05 pm ET
Horizon Pharma plc to Participate in Investor Conferences in November
DUBLIN, Ireland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will participate in the following conferences in November:...
Nov 02, 2017 04:05 pm ET
Horizon Pharma plc to Participate in Investor Conferences in November
DUBLIN, Ireland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that...
Oct 02, 2017 04:30 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, IRELAND, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on October 1, 2017 of inducement restricted stock units for an aggregate of 99,771 ordinary shares to 37 new employees....
Sep 13, 2017 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 11, 2017 of an inducement restricted stock unit covering 64,056 ordinary shares and an inducement stock option to purchase up to 103,138 ordinary shares to Irina Konstantinovsky, executive vice president, chief hu...
Sep 11, 2017 08:00 am ET
Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer
DUBLIN, Ireland, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Irina Konstantinovsky executive vice president, chief human resources officer, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately....
Sep 05, 2017 04:05 pm ET
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
DUBLIN, Ireland, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 1, 2017 of inducement restricted stock units for an aggregate of 227,073 shares of common stock to 52 new employees....
Aug 07, 2017 07:00 am ET
Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
-- Second-Quarter 2017 Net Sales of $289.5 Million; Up 12 Percent, Above Expectations ---- Second-Quarter 2017 Net Loss of $209.5 Million; Adjusted EBITDA of $127.0 Million, Above Expectations ---- Second-Quarter 2017 GAAP Operating Cash Flow of $47.9 Million; Non-GAAP Operating Cash Flow of $86.4 Million ---- Second-Quarter 2017 Net Sales of Rare Disease Medicines Increased 70 Percent ---- Completed Acquisition of River Vision Development Corp., Adding Late-Stage Development Biologic Teprotumumab ---- Completed Sale of EMEA Marketing Rights for PROCYSBI® and QUINSAIRTM ---- Increasing Full-Ye...
Jul 25, 2017 08:00 am ET
Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community
DUBLIN, Ireland, July 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today introduced CGD Connections, an initiative by and for people impacted by chronic granulomatous disease (CGD), a rare genetic disease that weakens the immune system and can lead to repeated, severe infections.1,2...
May 23, 2017 04:05 pm ET
Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middl
DUBLIN, Ireland, May 23, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has reached an agreement to sell a European subsidiary that owns the marketing rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A. (Chiesi) for ...
May 09, 2017 10:31 am ET
Investors: Covered Call reports for Horizon Pharma, JD.com, JP Morgan Chase, Kite Pharma and Micron include trade ideas that offer returns of 20% or more!
CHICAGO, May 9, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, JD, JPM, KITE, and MU....
May 01, 2017 07:00 am ET
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older
DUBLIN, Ireland, May 01, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) to expand the age range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to people two months of age and older who have urea cycle disorders (UCDs) that cannot be managed by dietary protein restric...
Mar 02, 2017 08:00 am ET
Horizon Pharma plc Announces Urea Cycle Disorders Medical Foods and Supplements Financial Assistance Program
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced support of a program developed by the National Organization for Rare Disorders (NORD) to help people with Urea Cycle Disorders (UCDs) seeking assistance with high out-of-pocket costs associated with the purchase of medical foods and supplements for their low-protein dietary needs.  ...
Feb 28, 2017 09:31 am ET
Stock Option covered-call reports for Apple, 21st Century Fox, Horizon Pharma, Regions Financial Corporation and Verizon Communications
CHICAGO, Feb. 28, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, FOXA, HZNP, RF, and VZ....
Feb 28, 2017 08:00 am ET
Horizon Pharma plc Launches RAREis™ Campaign Elevating Faces of the Rare Disease Community
DUBLIN, Ireland, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the launch of RAREis™, an initiative that aims to elevate the voices, faces and experiences of people living with rare diseases, as well as Horizon’s programs and resources for the rare disease community.  The launch of RAREis coincides with international Rare Disease Day®, a global observance rec...
Feb 27, 2017 07:00 am ET
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
-- Fourth-Quarter 2016 Net Sales of $310.3 Million; Up 27 Percent ---- Fourth-Quarter 2016 Net Loss of $130.5 Million(1); Adjusted EBITDA of $136.4 Million --...
Jan 17, 2017 12:00 pm ET
Global Genes® and Horizon Pharma plc Partner to Offer Nephropathic Cystinosis Scholarships
ALISO VIEJO, Calif. and DUBLIN, Jan. 17, 2017 /PRNewswire-USNewswire/ -- Global Genes® and Horizon Pharma plc (NASDAQ: HZNP) announced the Horizon Nephropathic Cystinosis Scholarship (HNCS), an exclusive opportunity for people living with nephropathic cystinosis to further their education and pursue opportunities toward long-term career goals.  Applicants can apply for the scholarship by visiting the Global Genes website. ...
Dec 08, 2016 04:10 pm ET
Horizon Pharma plc to Participate in Investor Conference in December
DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will participate in the following conference in December:...
Nov 14, 2016 09:31 am ET
InvestorsObserver releases covered-call reports for Micron, Smith & Wesson, Horizon Pharma, JC Penney and Procter & Gamble
CHICAGO, Nov. 14, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, JCP, MU, PG, and SWHC....
Nov 04, 2016 07:00 am ET
Horizon Pharma plc to Participate in Investor Conferences in November
DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will participate at the following conferences in November:...
Oct 25, 2016 08:39 am ET
Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.
      -    Adds Two Rare Disease Medicines and Further Diversifies Company Revenue -          ...
Oct 20, 2016 07:00 am ET
Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes
DUBLIN, Ireland, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) (“Horizon”), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Horizon Pharma, Inc. and Horizon Pharma USA, Inc., its wholly owned subsidiaries, have priced their offering of $300 million aggregate principal amount of 8.750% senior notes due 2024.  The note offering is expected to close on or about October 25, 2016, subject to customary closi...
Oct 13, 2016 07:45 am ET
Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Borrow Incremental Term Loans under its Existing Senior Secured Credit Facility
DUBLIN, Ireland , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) (“Horizon”), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Horizon Pharma, Inc. and Horizon Pharma USA, Inc., its wholly owned subsidiaries, intend, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million aggregate principal amount of incremental te...
Oct 13, 2016 07:00 am ET
Horizon Pharma plc Named One of the Country's Best Medium Workplaces by Fortune Magazine
DUBLIN, Ireland, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has been selected to Fortune’s “Best Small and Medium Workplaces” list.  Horizon ranked #22 on the Best Medium Workplaces List....
Oct 11, 2016 04:05 pm ET
Horizon Pharma plc to Host Third-Quarter 2016 Conference Call and Webcast on November 7, 2016
DUBLIN, Ireland, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third-quarter 2016 financial results will be released on Monday, November 7, 2016.  Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results....
Sep 29, 2016 08:00 am ET
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines.  The rebate agreement begins on October 1, 2016. ...
Sep 12, 2016 07:00 am ET
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
-  Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million  -...
Sep 06, 2016 07:00 am ET
Horizon Pharma plc to Participate in Morgan Stanley Global Healthcare Conference
DUBLIN, Ireland, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016 in New York City, NY....
Sep 01, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer.  Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller.  She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration  Degree from the Ivey Business School, University...
Sep 01, 2016 05:30 pm ET
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer.  Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller.  She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration  Degree from the Ivey Business School, Uni...
Aug 18, 2016 07:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
DUBLIN, Ireland, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for U.S. patent application number 14/563,000 (U.S. publication number 2015-0141388), entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon’s U.S. approved medicine ...
Jul 07, 2016 07:00 am ET
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016
DUBLIN, Ireland, July 07, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its second-quarter 2016 financial results will be released on Monday, August 8, 2016.  Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results....
Jun 29, 2016 07:00 am ET
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid to Expand Age Range for Management of Urea Cycle Disorders
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to expand the age range for chronic management of urea cycle disorders (UCDs) in adult and pediatric patients from two years of age to two months of age and older.
Jun 27, 2016 04:15 pm ET
Horizon Pharma plc Added to Russell 2000(R) and 3000(R) Indexes
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it has been added to the U.S. Russell 2000® and 3000® Indexes, effective today, as part of the 2016 Russell indexes reconstitution.
Jun 02, 2016 07:00 am ET
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Jefferies 2016 Healthcare Conference at 2 p.m. EDT on June 9, 2016 in New York City, NY.
Jun 01, 2016 07:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/980,639, entitled "Method for Delivering a Pharmaceutical Composition to Patient in Need Thereof" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.
May 19, 2016 07:00 am ET
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliate has entered into a definitive agreement with Boehringer Ingelheim International GmbH ("Boehringer Ingelheim") to acquire the rights to interferon gamma-1b, which Boehringer Ingelheim commercializes under the trade names IMUKIN®, IMUKINE®, IMMUKIN® and IMMUKINE® in an estimated 30 countries
May 18, 2016 05:45 pm ET
Horizon Pharma plc to Participate in UBS Global Healthcare Conference
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that Timothy P. Walbert, chairman, president and chief executive officer, will present at the UBS Global Healthcare Conference at 11 a.m. EDT on May 25, 2016 in New York City, NY.
May 12, 2016 08:00 am ET
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Marilyn Vetter, vice president, government and public affairs, has been named a 2016 Healthcare Businesswomen's Association (HBA) Luminary. Marilyn will be honored today at the 27th annual Woman of the Year event in New York.
May 12, 2016 07:00 am ET
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Teligent, Inc. to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).
May 11, 2016 07:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering KRYSTEXXA(R) (pegloticase)
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 13/379,704 (U.S. publication number 2012-0301454), entitled "Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy" that
May 09, 2016 07:00 am ET
Horizon Pharma plc Announces First-Quarter 2016 Financial Results
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first-quarter 2016 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.